Abstract

Chronic stimulation of CD8+ T cells triggers exhaustion, a distinct differentiation state with diminished effector function. Exhausted cells exist in multiple differentiation states, from stem-like progenitors that are the key mediators of the response to checkpoint blockade, through to terminally exhausted cells. Due to its clinical relevance, there is substantial interest in defining the pathways that control differentiation and maintenance of these subsets. Here, we show that chronic antigen induces the anergy-associated transcription factor EGR2 selectively within progenitor exhausted cells in both chronic LCMV and tumours. EGR2 enables terminal exhaustion and stabilizes the exhausted transcriptional state by both direct EGR2-dependent control of key exhaustion-associated genes, and indirect maintenance of the exhausted epigenetic state. We show that EGR2 is a regulator of exhaustion that epigenetically and transcriptionally maintains the differentiation competency of progenitor exhausted cells.

Exhausted T cells arise when chronic activation triggers functional defects. Here the authors show that chronic antigenic stimulation in both tumour and infection models induces the expression of EGR2, which drives and stabilises exhausted cell epigenetic and transcriptional identity.

Details

Title
Antigen-driven EGR2 expression is required for exhausted CD8+ T cell stability and maintenance
Author
Wagle, Mayura V 1 ; Vervoort, Stephin J 2 ; Kelly, Madison J 3   VIAFID ORCID Logo  ; Van Der Byl Willem 4   VIAFID ORCID Logo  ; Peters, Timothy J 5   VIAFID ORCID Logo  ; Martin, Ben P 3 ; Martelotto, Luciano G 6   VIAFID ORCID Logo  ; Nüssing Simone 2 ; Ramsbottom, Kelly M 3 ; Torpy, James R 5   VIAFID ORCID Logo  ; Knight, Deborah 3 ; Reading Sinead 3 ; Thia Kevin 3 ; Miosge, Lisa A 1 ; Howard, Debbie R 1 ; Gloury Renee 7 ; Gabriel, Sarah S 7 ; Utzschneider, Daniel T 8   VIAFID ORCID Logo  ; Oliaro, Jane 9   VIAFID ORCID Logo  ; Powell, Jonathan D 10 ; Luciani Fabio 4 ; Trapani, Joseph A 2 ; Johnstone, Ricky W 2   VIAFID ORCID Logo  ; Kallies Axel 8   VIAFID ORCID Logo  ; Goodnow, Christopher C 11   VIAFID ORCID Logo  ; Parish, Ian A 12   VIAFID ORCID Logo 

 Australian National University, John Curtin School of Medical Research, ACT, Australia (GRID:grid.1001.0) (ISNI:0000 0001 2180 7477) 
 Peter MacCallum Cancer Centre, Melbourne, Australia (GRID:grid.1055.1) (ISNI:0000000403978434); University of Melbourne, Sir Peter MacCallum Department of Oncology, Melbourne, Australia (GRID:grid.1008.9) (ISNI:0000 0001 2179 088X) 
 Peter MacCallum Cancer Centre, Melbourne, Australia (GRID:grid.1055.1) (ISNI:0000000403978434) 
 The Kirby Institute for Infection and Immunity, UNSW, Sydney, Australia (GRID:grid.1005.4) (ISNI:0000 0004 4902 0432); University of New South Wales, Faculty of Medicine, Sydney, Australia (GRID:grid.1005.4) (ISNI:0000 0004 4902 0432) 
 Garvan Institute of Medical Research, Darlinghurst, Australia (GRID:grid.415306.5) (ISNI:0000 0000 9983 6924); University of New South Wales, Sydney, Australia (GRID:grid.1005.4) (ISNI:0000 0004 4902 0432) 
 University of Melbourne, Centre for Cancer Research, VCCC, Melbourne, Australia (GRID:grid.1008.9) (ISNI:0000 0001 2179 088X) 
 The University of Melbourne, The Peter Doherty Institute for Infection and Immunity, Melbourne, Australia (GRID:grid.1008.9) (ISNI:0000 0001 2179 088X); The University of Melbourne, Department of Microbiology and Immunology, Melbourne, Australia (GRID:grid.1008.9) (ISNI:0000 0001 2179 088X); The Walter and Eliza Hall Institute of Medical Research, Parkville, Australia (GRID:grid.1042.7) 
 The University of Melbourne, The Peter Doherty Institute for Infection and Immunity, Melbourne, Australia (GRID:grid.1008.9) (ISNI:0000 0001 2179 088X); The University of Melbourne, Department of Microbiology and Immunology, Melbourne, Australia (GRID:grid.1008.9) (ISNI:0000 0001 2179 088X) 
 Peter MacCallum Cancer Centre, Melbourne, Australia (GRID:grid.1055.1) (ISNI:0000000403978434); University of Melbourne, Sir Peter MacCallum Department of Oncology, Melbourne, Australia (GRID:grid.1008.9) (ISNI:0000 0001 2179 088X); Monash University, Department of Immunology, Central Clinical School, Melbourne, Australia (GRID:grid.1002.3) (ISNI:0000 0004 1936 7857) 
10  Johns Hopkins University of Medicine, Bloomberg~Kimmel Institute for Cancer Immunotherapy, Baltimore, USA (GRID:grid.21107.35) (ISNI:0000 0001 2171 9311) 
11  Australian National University, John Curtin School of Medical Research, ACT, Australia (GRID:grid.1001.0) (ISNI:0000 0001 2180 7477); University of New South Wales, Faculty of Medicine, Sydney, Australia (GRID:grid.1005.4) (ISNI:0000 0004 4902 0432); Garvan Institute of Medical Research, Darlinghurst, Australia (GRID:grid.415306.5) (ISNI:0000 0000 9983 6924) 
12  Australian National University, John Curtin School of Medical Research, ACT, Australia (GRID:grid.1001.0) (ISNI:0000 0001 2180 7477); Peter MacCallum Cancer Centre, Melbourne, Australia (GRID:grid.1055.1) (ISNI:0000000403978434); University of Melbourne, Sir Peter MacCallum Department of Oncology, Melbourne, Australia (GRID:grid.1008.9) (ISNI:0000 0001 2179 088X) 
Publication year
2021
Publication date
2021
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2526478301
Copyright
© The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.